Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1420720 · FYE Jun 30 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $1.39Day +2.21%Mkt cap $68M1Y +104.4%Off 52W high −63.6%Vol (1Y) 115.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 4,502 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest10.8% of sh out |
| Days to cover4.0d |
| 13F net flow (QoQ)+2.28% |
| Top-10 13F concentration74.2% |
| Next report (est.)2026-08-10 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$300,000 |
| Earnings (TTM)-$27.6M |
| ROE−101.5% |
| Net margin−4594.3% |
| Sales growth 3Y−40.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−28.0% |
| 1Y+104.4% |
| 3Y−86.1% |
| 5Y−99.8% |
| 10Y−100.0% |
| Since incept. (ann.)−36.5% |
Total return through 2026-07-30 · series begins 2008-08-19. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)115.3% |
| Ann. volatility (3Y)159.1% |
| Sharpe (1Y)1.15 |
| Sharpe (3Y)0.19 |
| Max drawdown (1Y)−56.0% |
| Max drawdown (3Y)−95.8% |
| Beta (3Y vs SPY)1.75 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 3.1M | $6M | 6.25% | +51.0% |
| Frazier Life Sciences Management, L.P. | 2.0M | $4M | 3.93% | +0.0% |
| EcoR1 Capital, LLC | 1.6M | $3M | 3.19% | −28.9% |
| MILLENNIUM MANAGEMENT LLC | 1.5M | $3M | 3.12% | new |
| Logos Global Management LP | 1.3M | $2M | 2.62% | −35.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.1M | $2M | 2.19% | new |
| Balyasny Asset Management L.P. | 1.0M | $2M | 2.03% | −7.8% |
| Ikarian Capital, LLC | 957,062 | $2M | 1.93% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | −$0.06 | — | — | — |
| 2025-12-31 | 2026-02-10 | −$0.09 | — | $0 | −100.0% |
| 2025-09-30 | 2025-11-12 | −$0.11 | — | $100,000 | — |
| 2025-06-30 | 2025-09-05 | — | — | $200,000 | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-10 is ESTIMATED from filing cadence (median gap 90d) — not company-confirmed.
